HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics announced an upcoming investor event at Mar-A-Lago Club on May 8, 2025. The event will discuss strategic initiatives including HOPE's interventional psychiatry clinic expansion and NRx's clinical pipeline progress.
Key discussion topics include: HOPE's recent clinic acquisitions, integration of digital health solutions, status of NRX-100 (preservative-free IV Ketamine) NDA following a $4.3M FDA filing fee waiver, a new patent filing for NRX-100 that could provide market exclusivity until 2045, and the Breakthrough Therapy Designation of NRX-101 for bipolar depression treatment. Dr. Jonathan Javitt, Chairman and CEO of NRx and Co-CEO of HOPE Therapeutics, will lead the discussion.
NRx Pharmaceuticals (NASDAQ:NRXP) e la sua controllata HOPE Therapeutics hanno annunciato un prossimo evento per investitori presso il Mar-A-Lago Club l'8 maggio 2025. L'incontro tratterà iniziative strategiche, tra cui l'espansione della clinica di psichiatria interventistica di HOPE e i progressi della pipeline clinica di NRx.
I temi principali includono: le recenti acquisizioni di cliniche da parte di HOPE, l'integrazione di soluzioni digitali per la salute, lo stato della NDA per NRX-100 (chetamina endovenosa senza conservanti) dopo l'esenzione della tassa FDA da 4,3 milioni di dollari, un nuovo deposito di brevetto per NRX-100 che potrebbe garantire l'esclusività di mercato fino al 2045, e la Designazione di Terapia Sperimentale per NRX-101 nel trattamento della depressione bipolare. La discussione sarà guidata dal Dr. Jonathan Javitt, Presidente e CEO di NRx e Co-CEO di HOPE Therapeutics.
NRx Pharmaceuticals (NASDAQ:NRXP) y su subsidiaria HOPE Therapeutics anunciaron un próximo evento para inversores en el Mar-A-Lago Club el 8 de mayo de 2025. El evento abordará iniciativas estratégicas, incluyendo la expansión de la clínica de psiquiatría intervencionista de HOPE y los avances en la pipeline clínica de NRx.
Los temas clave incluyen: las recientes adquisiciones de clínicas de HOPE, la integración de soluciones digitales de salud, el estado del NDA de NRX-100 (ketamina IV sin conservantes) tras la exención de la tasa de presentación de la FDA de 4,3 millones de dólares, una nueva solicitud de patente para NRX-100 que podría otorgar exclusividad en el mercado hasta 2045, y la Designación de Terapia Innovadora para NRX-101 en el tratamiento de la depresión bipolar. La discusión estará liderada por el Dr. Jonathan Javitt, presidente y CEO de NRx y co-CEO de HOPE Therapeutics.
NRx Pharmaceuticals (NASDAQ:NRXP)와 자회사 HOPE Therapeutics가 2025년 5월 8일 마라라고 클럽에서 투자자 행사를 개최할 예정이라고 발표했습니다. 이번 행사는 HOPE의 중재 정신과 클리닉 확장과 NRx의 임상 파이프라인 진행 상황 등 전략적 이니셔티브를 다룰 예정입니다.
주요 논의 주제는 HOPE의 최근 클리닉 인수, 디지털 헬스 솔루션 통합, FDA 제출 수수료 430만 달러 면제 후 NRX-100(보존제 없는 정맥 주사 케타민) NDA 현황, 2045년까지 시장 독점권을 제공할 수 있는 NRX-100 신규 특허 출원, 그리고 양극성 우울증 치료를 위한 NRX-101의 혁신 치료 지정입니다. 이번 논의는 NRx의 회장이자 CEO, HOPE Therapeutics의 공동 CEO인 Dr. Jonathan Javitt가 이끌 예정입니다.
NRx Pharmaceuticals (NASDAQ:NRXP) et sa filiale HOPE Therapeutics ont annoncé un prochain événement pour investisseurs au Mar-A-Lago Club le 8 mai 2025. Cet événement abordera des initiatives stratégiques, notamment l'expansion de la clinique de psychiatrie interventionnelle de HOPE et les avancées du pipeline clinique de NRx.
Les sujets clés incluent : les récentes acquisitions de cliniques par HOPE, l'intégration de solutions de santé numérique, le statut de la NDA pour NRX-100 (kétamine IV sans conservateurs) suite à une exonération des frais de dépôt FDA de 4,3 millions de dollars, un nouveau dépôt de brevet pour NRX-100 pouvant assurer une exclusivité commerciale jusqu'en 2045, ainsi que la désignation de thérapie révolutionnaire pour NRX-101 dans le traitement de la dépression bipolaire. La discussion sera animée par le Dr Jonathan Javitt, président-directeur général de NRx et co-PDG de HOPE Therapeutics.
NRx Pharmaceuticals (NASDAQ:NRXP) und seine Tochtergesellschaft HOPE Therapeutics kündigten eine bevorstehende Investorenveranstaltung im Mar-A-Lago Club am 8. Mai 2025 an. Bei der Veranstaltung werden strategische Initiativen besprochen, darunter die Expansion der interventionellen Psychiatrie-Klinik von HOPE und der Fortschritt der klinischen Pipeline von NRx.
Wichtige Diskussionsthemen sind: die jüngsten Klinikübernahmen von HOPE, die Integration digitaler Gesundheitslösungen, der Status der NDA für NRX-100 (konservierungsmittelfreies IV-Ketamin) nach einem Erlass der FDA-Einreichungsgebühr in Höhe von 4,3 Mio. USD, eine neue Patentanmeldung für NRX-100, die Marktexklusivität bis 2045 bieten könnte, sowie die Breakthrough Therapy Designation von NRX-101 zur Behandlung von bipolaren Depressionen. Die Diskussion wird von Dr. Jonathan Javitt, Vorsitzender und CEO von NRx sowie Co-CEO von HOPE Therapeutics, geleitet.
- None.
- None.
This discussion is being held to review previously-disclosed strategic initiatives across HOPE and NRx Pharmaceuticals, including expansion plans for the HOPE network of interventional psychiatry clinics and progress across the NRx clinical pipeline. Current investors who wish to attend are invited to contact the Company.
Key Topics to be Discussed, based on previously disclosed information:
- Recently announced HOPE clinic acquisitions and potential to scale HOPE's interventional psychiatry network
- Plans for integration of digital health solutions, including CRM-based technology and telepsychiatry capabilities, to unify clinical operations across the HOPE network
- Status of the New Drug Application (NDA) for NRX-100 (preservative-free IV Ketamine), following FDA's grant of a
$4.3 million - Recent filing of a patent for preservative-free ketamine (NRX-100). If granted, the patent could provide market exclusivity for NRX-100 into 2045
- Breakthrough Therapy Designation of NRX-101; currently preparing to file an NDA for Accelerated Approval in patients with bipolar depression and suicidality or akathisia
Dr. Jonathan Javitt, MD, MPH, Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics will lead the discussion.
"We are excited to continue to meet with our investor community to discuss the significant progress we've made recently," said Dr. Javitt. "Our continued focus on expanding access to innovative treatments and delivering on key regulatory and operational milestones underscores the potential of HOPE and NRx's leadership in mental health innovation."
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetic stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: | ||
Matthew Duffy | Brian Korb | |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, astr partners | |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-to-host-investor-event-at-mar-a-lago-club-on-may-8-2025-302447200.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What will be discussed at the NRXP investor event at Mar-A-Lago on May 8, 2025?
What is the status of NRX-100's FDA application for NRXP?
How long could NRXP's market exclusivity last for NRX-100 if the patent is granted?
What is the current status of NRXP's NRX-101 drug development?
